microdosing tirzepatide for menopause GLP-1s for Menopause-Related Weight Gain The GLP-1/GIP dual-receptor agonist tirzepatide

26.8% Abstinence Without GLP-1 The placebo + NRT group only achieved 26.8% abstinence after 6 weeks, indicating additional benefit of GLP-1s

It is not yet approved for general medical use and remains in Phase 3 clinical trials, where researchers are assessing long-term safety, durability of weight loss, and broader metabolic benefits

Most people experience the first signs of semaglutide-related nausea within one to two days after injection, with peak discomfort typically occurring mid-week

Updated May 5, 2026

Log in SKU: BRC-1410 Description Phosphatidylcholine supplies a supplemental source of this important phospholipid

If the cap looks loose, has been punctured too many times, or is not sealing correctly, the medication inside might not be safe to use